Multiparametric magnetic resonance imaging-based predictive model for chemotherapy response in colorectal cancer patients with gene mutations

Table 1 Univariate analysis of factors affecting efficacy of chemotherapy in patients with colorectal cancer

Baseline data		Favorable group (n = 60)	Unfavorable group (n = 50)	t/χ2	P value
Age (years)		56.34 ± 3.11	56.27 ± 2.73	0.124	0.901
Sex	Male	36	32	0.185	0.912
	Female	24	18
BMI (kg/m2)		21.13 ± 1.34	21.27 ± 1.41	0.533	0.595
Tumor location	Left side	24	21	0.064	0.996
	Right side	18	15
	Rectum	18	14
Comorbid underlying diseases	Yes	15	10	0.388	0.824
	N/A	45	40
Family history of colorectal cancer	Yes	3	2	0.063	0.969
	N/A	57	48
Type of pathology	Adenocarcinoma	34	29	0.020	0.888
	Miscellaneous	26	21
Clinical stage	Stage II	37	24	2.077	0.354
	Stage III	23	26
Degree of tumor differentiation	Poorly differentiated	23	10	8.952	0.030
	Moderately differentiated	25	11
	Well-differentiated	12	19
T2 signal strength grade		2.62 ± 0.51	3.43 ± 0.64	7.387	< 0.001
Distance from the lower edge of the tumor to the anus (anal margin; cm)		6.86 ± 1.31	5.11 ± 1.08	7.546	< 0.001
MRI lymph node metastasis	Yes	11	32	23.891	< 0.001
	N/A	49	18

BMI: Body mass index; N/A: Not available; MRI: Magnetic resonance imaging.

Table 2 Multivariate Logistics regression analysis of risk factors affecting efficacy of chemotherapy

Risk factor	Β value	SE value	Ward value	OR value	95%CI	P value	Tolerance	VIF
Degree of tumor differentiation	0.785	0.348	5.092	2.193	1.109-4.338	< 0.001	0.954	1.021
T2 signal strength grading	0.126	0.064	3.861	1.134	1.000-1.286	< 0.001	0.971	1.012
Distance between lower edge of tumor and anus	0.748	0.264	8.020	2.112	1.259-3.543	< 0.001	0.967	1.031
MRI-detected lymph node metastasis	0.449	0.211	4.532	1.567	1.036-2.370	< 0.001	0.975	1.027

VIF: Variance inflation factor; MRI: Magnetic resonance imaging.